The DCGI’s Subject Expert Committee recommends Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients above 9 years to 26 years of age.
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
Every year in India, 122,844 women are diagnosed with cervical cancer and 67,477 die from the disease.
The HPV vaccine reduces a woman’s risk of cervical cancer. Men cannot develop cervical cancer, but the HPV vaccine may prevent genital warts, penile cancer, anal cancer, and the spread of HPV to sexual partners.
